NASDAQ:ELYM - Get Free Report ) rose 0.5% during trading on Monday . The stock traded as high as $4.12 and last traded at $3.87. Approximately 95,362 shares traded hands during trading, a decline of 84% from the average daily volume of 583,013 shares. The stock had previously closed at $3.85.
Get Eliem Therapeutics alerts:
Sign Up
Eliem Therapeutics Stock Down 3.1 % The firm has a market cap of $103.95 million, a PE ratio of -2.55 and a beta of 0.51. The company's 50 day moving average price is $3.00 and its two-hundred day moving average price is $2.78.
Institutional Investors Weigh In On Eliem Therapeutics A hedge fund recently raised its stake in Eliem Therapeutics stock. BML Capital Management LLC grew its position in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report ) by 22.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,938,263 shares of the company's stock after acquiring an additional 355,093 shares during the quarter. Eliem Therapeutics comprises about 4.7% of BML Capital Management LLC's portfolio, making the stock its 8th largest position. BML Capital Management LLC owned 7.15% of Eliem Therapeutics worth $5,098,000 at the end of the most recent reporting period. Institutional investors own 69.76% of the company's stock.
About Eliem Therapeutics (
Get Free Report )
Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.
Read More Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
